Journal article
Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: A secondary analysis of the HERO trial
SV Badve, L Zhang, JS Coombes, EM Pascoe, A Cass, P Clarke, P Ferrari, SP McDonald, AT Morrish, E Pedagogos, V Perkovic, D Reidlinger, A Scaria, R Walker, LA Vergara, CM Hawley, DW Johnson, E D'Almeida, R Fassett, C Kirkpatrick Show all
Canadian Journal of Kidney Health and Disease | Published : 2015
Abstract
Background: Erythropoiesis stimulating agent (ESA)-resistant anemia is common in chronic kidney disease (CKD). Objectives: To evaluate the determinants of severity of ESA resistance in patients with CKD and primary ESA-resistance. Design: Secondary analysis of a randomized controlled trial (the Handling Erythropoietin Resistance with Oxpentifylline, HERO) Setting and patients: 53 adult patients with CKD stage 4 or 5 and primary ESA-resistant anemia (hemoglobin ≤120g/L, ESA resistance index [ERI] ≥1.0IU/kg/week/gHb for erythropoietin or ≥0.005μg/kg/week/gHb for darbepoeitin, no cause for ESA-resistance identified). Measurements: Iron studies, parathyroid hormone, albumin, liver enzymes, phosp..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Awarded by Roche Foundation for Anaemia Research
Awarded by Janssen-Cilag
Awarded by Amgen (Australia)